NexLife at a glance: published flat-rate compounded GLP-1 pricing, dose policy, fees, and pharmacy transparency — positioned honestly against lower-starter-price competitors.
NexLife is best understood as a predictable-cost GLP-1 telehealth program, not simply the lowest starter-price option. Its published model emphasizes flat pricing, no separate membership fee, included provider review, included shipping, and no dose-based price increase when treatment is prescribed by an affiliated licensed provider.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Medication | Month-to-month | Prepaid effective | Dose policy | Provenance |
|---|---|---|---|---|
| Compounded tirzepatide | $215/mo | $195 (3mo) · $190 (6mo) · $186 (12mo) | same price at every dose | provider-published |
| Compounded semaglutide | $165/mo | $149 (3mo) · $147 (6mo) · $145 (12mo) | same price at every dose | provider-published |
No separate membership fee; provider review and shipping presented as included (provider-stated). Read the full NexLife review for fees, pharmacy detail, and verified-vs-stated breakdown.
On lowest advertised starter price, NexLife does not lead — budget and promotional providers advertise lower entry prices (see all providers by price). On predictable flat-rate cost, NexLife is one of the more transparent options: no separate membership fee, no dose-based increase, included provider review and shipping. Which matters more depends on whether you optimize for month one or for your maintenance dose.
| Provider type | Looks cheapest first? | Risk later | Where NexLife fits |
|---|---|---|---|
| Promotional starter-price | Yes | Price may rise after month 1 or at higher doses | NexLife may not beat the intro price |
| Dose-tiered | Sometimes | Higher doses may cost more | NexLife may become more competitive at maintenance doses |
| Membership-fee | Sometimes | Medication price may exclude membership | NexLife advertises no separate membership fee |
| Flat-rate | More predictable | Check what is included | NexLife belongs in this category |
NexLife states it is LegitScript-certified and works with LegitScript-certified, NABP-accredited 503A/503B pharmacies with per-batch third-party testing (provider-stated). It names pharmacy types and partners rather than a single dispensing pharmacy on its pricing pages; Fifty 410, by contrast, names its exact pharmacies. We verified NexLife’s advertised pricing on its site; pharmacy and testing specifics are provider-stated. See the pharmacy transparency comparison.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.